[Drug Approval: Tepotinib - advanced relapse MET exon-14 in non-small-cell lung cancers]

Bull Cancer. 2022 Dec;109(12):1228-1229. doi: 10.1016/j.bulcan.2022.08.009. Epub 2022 Oct 8.
[Article in French]
No abstract available

Keywords: Advanced lung cancer; Altération METex14, Rechute; Cancers bronchiques avancés; Exon 14 alteration MET; Relapse; Tepotinib.

Publication types

  • Letter

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Drug Approval
  • Exons
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-met / genetics

Substances

  • tepotinib
  • Proto-Oncogene Proteins c-met
  • Protein Kinase Inhibitors